|
|
Article: Coley's VaxImmune Adjuvant Subject Of $37M Merck Deal.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Coley Pharmaceutical Group Inc. will get $4 million up front and stands to receive up to $33 million in potential milestones as part of a licensing deal that gives Merck & Co. Inc. rights to VaxImmune, an adjuvant technology, for use in developing vaccines for infectious diseases and Alzheimer's.
Under the terms, Coley also would receive royalties on any product sales from the collaboration. In exchange, Merck holds nonexclusive rights to the technology for certain infectious disease fields and Alzheimer's disease, and retains an option to add additional disease areas in the future. The deal is similar to earlier agreements Coley signed ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|